DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR XTANDI

« Back to Dashboard

Clinical Trials for Xtandi

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00510718	A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer	Active, not recruiting	Medivation, Inc.	Phase 1	This is a multi-center open-label dose-escalation study of a novel compound (MDV3100) to treat patients with castration-resistant (hormone-refractory) prostate cancer. Additional patients will be enrolled in expanded cohorts at doses determined to be tolerable. Patients who tolerate the drug and do not progress will be allowed to continue to look for PSA response.
NCT01302041	A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy	Active, not recruiting	Medivation, Inc.	Phase 2	To evaluate the effect of enzalutamide on prostate specific antigen (PSA) level in men with prostate cancer.
NCT01302041	A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy	Active, not recruiting	Astellas Pharma Inc	Phase 2	To evaluate the effect of enzalutamide on prostate specific antigen (PSA) level in men with prostate cancer.
NCT01534052	A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100	Active, not recruiting	Medivation, Inc.	Phase 2	A study to assess the safety of continued administration of MDV3100 in subjects with Prostate Cancer who have already undergone treatment with MDV3100 and showed benefit.
NCT01534052	A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100	Active, not recruiting	Astellas Pharma Inc	Phase 2	A study to assess the safety of continued administration of MDV3100 in subjects with Prostate Cancer who have already undergone treatment with MDV3100 and showed benefit.

Clinical Trial Conditions for Xtandi

Condition Name

Condition Name for Xtandi
Intervention	Trials
Prostate Cancer	28
Stage IV Prostate Cancer	13
Metastatic Prostate Carcinoma	8
Hormone-Resistant Prostate Cancer	8

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Xtandi
Intervention	Trials
Prostatic Neoplasms	81
Adenocarcinoma	14
Carcinoma	11
Breast Neoplasms	6

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Xtandi

Trials by Country

Trials by Country for Xtandi
Location	Trials
United States	315
Canada	40
United Kingdom	32
Spain	29
France	26

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Xtandi
Location	Trials
California	22
New York	21
Texas	19
Maryland	16
Michigan	14

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Xtandi

Clinical Trial Phase

Clinical Trial Phase for Xtandi
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	9
Phase 2/Phase 3	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Xtandi
Clinical Trial Phase	Trials
Recruiting	53
Active, not recruiting	20
Not yet recruiting	15

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Xtandi

Sponsor Name

Sponsor Name for Xtandi
Sponsor	Trials
Medivation, Inc.	40
Astellas Pharma Inc	25
National Cancer Institute (NCI)	19

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Xtandi
Sponsor	Trials
Industry	103
Other	75
NIH	19

Export unavailable in trial.
Subscribe for complete access.